Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hearn

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Biochemistry|October 3, 2001
Kinetic analysis of product inhibition in human manganese superoxide dismutaseA S Hearn, M E Stroupe, D E Cabelli, et al.
Biochemistry|March 12, 2003
Catalytic and structural effects of amino acid substitution at histidine 30 in human manganese superoxide dismutase: insertion of valine C gamma into the substrate access channelAmy S Hearn, M Elizabeth Stroupe, Diane E Cabelli, et al.
Experimental Cell Research|January 10, 1996
Evidence that disruption of connexon particle arrangements in gap junction plaques is associated with inhibition of gap junctional communication by a glycyrrhetinic acid derivativeG S Goldberg, A P Moreno, J F Bechberger, et al.
The Journal of Biological Chemistry|November 26, 2003
Amino acid substitution at the dimeric interface of human manganese superoxide dismutaseAmy S Hearn, Li Fan, James R Lepock, et al.
Biochemistry|June 2, 2004
Role of hydrogen bonding in the active site of human manganese superoxide dismutaseWilliam B Greenleaf, J Jefferson P Perry, Amy S Hearn, et al.
The Journal of Biological Chemistry|December 23, 2003
Potent anti-tumor effects of an active site mutant of human manganese-superoxide dismutase. Evolutionary conservation of product inhibitionChristopher A Davis, Amy S Hearn, Bradley Fletcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatinA J Gelderblom, W J Loos, M J de Jonge, et al.
Journal of Fish Biology|October 5, 2013
Assessing the sensitivity of habitats to fishing: from seabed maps to sensitivity mapsN C Eno, C L J Frid, K Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancerV M Herben, V R Panday, D J Richel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Biochemistry|October 3, 2001
Kinetic analysis of product inhibition in human manganese superoxide dismutaseA S Hearn, M E Stroupe, D E Cabelli, et al.
Biochemistry|March 12, 2003
Catalytic and structural effects of amino acid substitution at histidine 30 in human manganese superoxide dismutase: insertion of valine C gamma into the substrate access channelAmy S Hearn, M Elizabeth Stroupe, Diane E Cabelli, et al.
Experimental Cell Research|January 10, 1996
Evidence that disruption of connexon particle arrangements in gap junction plaques is associated with inhibition of gap junctional communication by a glycyrrhetinic acid derivativeG S Goldberg, A P Moreno, J F Bechberger, et al.
The Journal of Biological Chemistry|November 26, 2003
Amino acid substitution at the dimeric interface of human manganese superoxide dismutaseAmy S Hearn, Li Fan, James R Lepock, et al.
Biochemistry|June 2, 2004
Role of hydrogen bonding in the active site of human manganese superoxide dismutaseWilliam B Greenleaf, J Jefferson P Perry, Amy S Hearn, et al.
The Journal of Biological Chemistry|December 23, 2003
Potent anti-tumor effects of an active site mutant of human manganese-superoxide dismutase. Evolutionary conservation of product inhibitionChristopher A Davis, Amy S Hearn, Bradley Fletcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatinA J Gelderblom, W J Loos, M J de Jonge, et al.
Journal of Fish Biology|October 5, 2013
Assessing the sensitivity of habitats to fishing: from seabed maps to sensitivity mapsN C Eno, C L J Frid, K Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancerV M Herben, V R Panday, D J Richel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Pageof 4